Employees: 67
Size Prothena (PRTA) is a United States Health Care company (Biotechnology) with a market value of $429M, the 2789th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.35 on 18 Nov 2026.
Performance Over six months the shares fell 10.7%, against -19.5% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 347.4% over the last twelve months (peer median -1.8%); the operating margin is -73.0% (peer median -7.3%).
Valuation It trades at 3.1× enterprise value to sales against a peer median of 10.3× (5th cheapest of 16).
Short interest Short interest is 15.4% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $52.7M | $9.68M | $135M | $91.4M | $53.9M |
| Revenue growth | — | -93% | +48% | +70% | — |
| Gross profit | $49.0M | $5.98M | $132M | $83.0M | $47.2M |
| EBITDA | -$34.8M | -$181M | -$151M | -$183M | -$125M |
| Net income | -$24.0M | -$244M | -$122M | -$147M | -$117M |
| Free cash flow | -$30.8M | -$164M | -$150M | -$137M | -$109M |
| Capital expenditure | $716,408 | $138,000 | $298,000 | $2.81M | $464,000 |
| Total debt | $6.26M | $8.37M | $10.8M | $11.8M | $6.47M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PRTA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.8% | -13.3% | 3rd highest of 21 |
| 6-month return | -10.7% | -19.5% | 9th highest of 21 |
| Distance from 52-week high | -29.2% | -42.7% | 3rd highest of 21 |
| Revenue growth (TTM) | +347.4% | -1.8% | 2nd highest of 17 |
| Operating margin | -73.0% | -7.3% | 5th lowest of 17 |
| EV / Sales | 3.1× | 10.3× | 5th cheapest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | 3.1× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 2.6× | -19.5% | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 12.3× | 5.3% | +70.5% |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 14.6× | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 4.0× | 2.1% | +0.5% |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | 2.9× | 4.0% | -62.3% |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 2.2× | 7.7% | +7.3% |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | 3.3× | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | 215.1× | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | 908.6× | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | 10.6× | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | 9.9× | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | 10.3× | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | 1.0× | -15.3% | +197.3% |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | 84.4× | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | 11.8× | n/a | n/a |